FACTBOX-Spreads of U.S. mergers and acquisitions

Tue Apr 14, 2009 4:57pm EDT

 (We are planning to discontinue this factbox in 90 days if there are no objections from
clients. Please email megan.davies@thomsonreuters.com with any comments on this issue.
thanks)
 April 14 (Reuters) - The following list shows the arbitrage spread for proposed
mergers and acquisitions of U.S. companies.
 Historically, the wider the spread, the more investors doubt a deal will close.
 Arbitrage spreads measure the difference between the offered takeover price and the
target company's current trading price.
 For real-time spreads, go to <US/ARB/MENU>
ACQUIRER         TARGET              RIC       DEAL VALUE*  PRICE/SHARE   SPREAD %
Pfizer           Wyeth               WYE.N     66,825.00    46.28             9.46
Merck & Co       Schering Plough     SGP.N     38,609.15    25.52             9.21
NRG Energy       Calpine             CPN.N     10,916.43    9.79              5.48
Thoratec Corp    HeartWare Intl      HTWR.OQ   9,392.76     30.90            18.85
Exelon           NRG Energy          NRG.N     6,237.66     22.84            24.62
CenturyTel       Embarq              EQ.N      5,744.34     37.04             1.49
Agrium           CF Industries Hldgs CF.N      3,652.31     74.54             2.15
Fidelity Natl    Metavante Tech      MV.N      2,943.87     26.33             2.11
Consortium       Post Properties     PPS.N     2,054.24     47.00           258.78
CF Industries    Terra Ind           TRA.N     2,051.31     33.12            16.58
Validus Hlds     IPC Holdings        IPCR.OQ   1,677.41     28.50             3.99
Pulte Homes      Centex              CTX.N     1,341.58     9.95              2.20
Gilead Sciences  CV Therapeutics     CVTX.OQ   1,284.68     20.00              .20
Magellan Mid Prt Magellan Mid Hldgs  MGG.N     1,147.91     19.48             5.25
NOTE: * Deal values in millions of U.S. dollars
SOURCE: Reuters
 (Compiled by Oswald Blackwood)
 (For more M&A news and our DealZone blog, go to
here)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.